Formulated.

Formulated icon

Formulated for
cost reform.

Cost reform icon

Cost of cancer care represents a significant financial burden to patients. Price increases have driven up the cost of oncology supportive care.1

Next

Neulasta® (pegfilgrastim) Historical Prices in the US1

Pegfilgrastim WAC

Consumer Price Index*

Wholesale acquisition cost (WAC) has more than doubled since 2006+132%

+27%

Competition
for a change

Competition for a change

A major contributor to the rising cost of care, biologics account for 40% of prescription drug spending in the United States, which reached a record $425 billion in 2015.2 Biosimilars such as UDENYCA® may positively impact patients, providers, and the healthcare system at large.

Benefits of Biosimilars

Providers icon

PROVIDERS2,3

  • Provides a choice that has the potential to lower the financial burden
  • May help increase patient access
Patients icon

PATIENTS2,3

  • Helps decrease overall financial burden
  • Increases access to treatment options
System icon

SYSTEM2,3

  • Offsets the burden of increasing healthcare costs in areas such as oncology
  • Potential savings due to more treatment choices and increased competition
  • May free up resources for other important aspects of healthcare

PROVIDERS2,3

  • Provides a choice that has the potential to lower the financial burden
  • May help increase patient access

PATIENTS2,3

  • Helps decrease overall financial burden
  • Increases access to treatment options

SYSTEM2,3

  • Offsets the burden of increasing healthcare costs in areas such as oncology
  • Potential savings due to more treatment choices and increased competition
  • May free up resources for other important aspects of healthcare

UDENYCA® offers SIGNIFICANT COST SAVINGS for your patients and practice4

Wholesale Acquisition Cost (WAC)

Neulasta®

~$6200

UDENYCA®

$4175

UDENYCA® delivers high-quality treatment and the reliable outcomes that you expect with Neulasta®, but with 32% cost savings
for your patients and practice.4,5

UDENYCA® delivers high-quality treatment and the reliable outcomes that you expect with Neulasta®, but with 32% cost savings for your patients and practice.4,5

References: 1. United States Bureau of Labor Statistics. SHA National Data, MAT. January 2018. 2. Biosimilars: a safe & effective option for patients. The Biosimilars Council. Updated January 2018. Accessed July 22, 2020. http://biosimilarscouncil.org/wp-content/uploads/2017/11/Biosimilars-Fact-Sheet_Updated-10-9-17-Final.pdf 3. Biosimilars overview. Biosimilars Forum. Accessed May 19, 2020. http://www.biosimilarsforum.org/sites/default/files/uploads/biosimilars_overview_032816opt_-_copy_0.pdf 4. First Databank, Inc. Pricing Compendia. 5. UDENYCA® (pegfilgrastim-cbqv) package insert. Redwood City, CA: Coherus BioSciences, Inc.; 2019.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

    WARNINGS AND PRECAUTIONS:

  • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
  • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA® in patients with ARDS.
  • Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA® in patients with serious allergic reactions.
  • Fatal sickle cell crises: Have occurred.
  • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA® if causality is likely.

ADVERSE REACTIONS:

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

UDENYCA® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use
UDENYCA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please see Full Prescribing Information.

IMPORTANT SAFETY INFORMATION

CONTRAINDICATION:

Patients with a history of serious allergic reaction to human granulocyte colony-stimulating factors such as pegfilgrastim or filgrastim products.

    WARNINGS AND PRECAUTIONS:

  • Fatal splenic rupture: Evaluate patients who report left upper abdominal or shoulder pain for an enlarged spleen or splenic rupture.
  • Acute respiratory distress syndrome (ARDS): Evaluate patients who develop fever, lung infiltrates, or respiratory distress. Discontinue UDENYCA® in patients with ARDS.
  • Serious allergic reactions, including anaphylaxis: Permanently discontinue UDENYCA® in patients with serious allergic reactions.
  • Fatal sickle cell crises: Have occurred.
  • Glomerulonephritis: Evaluate and consider dose-reduction or interruption of UDENYCA® if causality is likely.

ADVERSE REACTIONS:

Most common adverse reactions (≥ 5% difference in incidence compared to placebo) are bone pain and pain in extremity.

To report SUSPECTED ADVERSE REACTIONS, contact Coherus BioSciences at 1-800-4-UDENYCA (1-800-483-3692) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

INDICATION

UDENYCA® is a leukocyte growth factor indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.

Limitations of Use
UDENYCA® is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.

Please see Full Prescribing Information.